What Are Analysts Recommending for ANTM and CI?

On April 12, Anthem (ANTM) closed at $252.85, 8.48% lower than its previous closing price, 14.95% higher than its 52-week low of $219.96, and 20.48% lower than its 52-week high of $317.99. The company’s market cap is $65.34 billion, and its PE, forward PE, PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios are 17.94x, 11.13x, 0.71x, 2.29x, and 16.61x, respectively.

Since its last earnings release on January 30, Anthem’s share price has fallen 14.80% from $296.78 on January 30 to $252.85 as of April 12.

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

On April 12, Cigna (CI) closed at $160.60, 2.08% lower than its previous closing price, 1.65% higher than its 52-week low of $158.00, and 29.13% lower than its 52-week high of $226.60. The company’s market cap is $59.27 billion, and its PE, forward PE, PS, PB, and PC ratios are 15.03x, 8.68x, 1.22x, 1.02x, and 15.37x, respectively.

Since its last earnings release on February 1, Cigna’s share price has fallen 17.22% from $194.01 on February 1 to $160.60 on April 12.

Wall Street analysts expect a potential upside of 41.55% for Anthem based on the company’s closing price on April 12. Analysts increased the company’s 12-month consensus target price from $349.45 in February to $358.14 in March and then reduced it to $357.90 in April. The current consensus analyst recommendation for the stock is a “buy.”

Of the 23 analysts covering Anthem stock, nine have rated it as a “strong buy,” ten have rated it as a “buy,” and four have rated it as a “hold.”

Analysts expect a potential upside of 48.79% for Cigna based on the company’s closing price on April 12. Analysts raised the company’s 12-month consensus target price from $239.57 in February to $240.64 in March but then reduced it to $238.95 in April. The current consensus analyst recommendation for the stock is a “buy.”

Of the 23 analysts covering Cigna stock, seven have rated the company as a “strong buy,” 12 have rated it as a “buy,” and four have rated it as a “hold.”